Zweli Mkhize, South Africa's health minister, has stated that downpayments made to Johnson & Johnson (J&J) and Pfizer for COVID-19 vaccines are not refundable under any circumstances, Reuters news agency reported on Wednesday.
South Africa is paying USD10 per dose for the J&J and Pfizer vaccines.
The health minister made the comments following South Africa's suspension of the rollout of J&J's vaccine due to a recommendation by US federal health agencies to pause its use because of rare cases of blood clots.
According to Reuters, this suspension is another setback in the country's efforts to immunise its population, after it shelved plans to kick-start vaccinations with AstraZeneca's vaccine in February because a small trial showed the shot offered minimal protection against mild to moderate illness from the dominant local coronavirus variant.
At a virtual meeting with a parliamentary committee, Mkhize stated that South Africa had to navigate "difficult and sometimes unreasonable" demands from vaccine manufacturers during negotiations. He added "As government we have found ourselves in a precarious position of having to choose between saving our citizens' lives and risking putting the country's assets into private companies' hands."
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine